Colony-stimulating factor 1 (CSF1) regulates microglia/macrophages proliferation, differentiation and survival thus, pharmacological treatments using CSF1 receptor (CSF1R) inhibitors had been used to ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

Macrophage from synovial tissue expresses CD14, CD68, CSF1R, HLA-DRA, and MARCO (35). Figure 1. Pro-inflammatory and pro-chondrogeneic macrophage pathways in cartilage injury/repair. It seems clear ...

在PVRI大会上展示的信息基于Gossamer Bio的新闻稿。公司将继续研究seralutinib的有效性和安全性，以满足肺动脉高压患者未得到满足的医疗需求。与所有临床研究一样，这些发现将在科学界接受进一步的审查和验证。

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

面对药物研发的迅速发展，2025年将有四款备受瞩目的创新药物有望获批，这些药物不仅为亟需治疗的患者带来了新的希望，同时也为我们提供了对未来医疗科技的思考。究竟这些新药有何特别之处？它们能否改善患者的生活质量？让我们一同探讨。

SAN DIEGO - Gossamer Bio, Inc. (NASDAQ:GOSS), a biopharmaceutical company in the clinical stage with a market capitalization of $225 million, has shared new research findings on its drug candidate ...

Chronic inflammation and bone loss are closely linked pathophysiologic events. The most typical example of inflammatory bone loss is seen in patients with rheumatoid arthritis who develop systemic ...

▎药明康德内容团队编辑根据PDUFA的预期目标日期，预计2025年2月，美国FDA将对4款创新药物的批准做出监管决定，本文将对这些疗法进行相关介绍。▲2025年2月有望在美国获批的新药（药明康德内容团队制图，点击可见大图）活性成分：Bentracimab适应症：逆转替格瑞洛及其活性代谢物的抗血小板作用公司名称：SERB ...

Treatment with a compound that suppressed a receptor called CSF1R improved the transplantation efficiency of myeloid cells… The use of obesity medications — approved drugs for treating ...

This important study investigates the signaling pathways regulating retinal regeneration. Convincing evidence shows that the sphingosine-1-phosphate (S1P) signaling pathway is inhibited following ...

The nervous system is a complex network of neurons and cells that carry messages to and from the brain and spinal cord to various parts of the body. Scientists led by the Institute of ...